Active — Not RecruitingNot Applicable

Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents

France50 participantsStarted 2017-05-29

Plain-language summary

Prospective research of Matrix Metalloproteinases (MMP) 2 and 9 as predictive biomarkers in metastatic kidney cancer patients treated with 2 anti angiogenic agents (Sunitinib or Pazopanib).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient male or female, aged of more than 18 years
✓. Patient with any of the following conditions:
✓. ECOG = 0 to 2
✓. Patient affiliated to, or beneficiary of, the national social security.
✓. Patient having signed informed consent

Exclusion criteria

✕. Patient previously treated with anti-angiogenic agents.
✕. Person in an emergency situation, adult subject to a legal protection measure (a guardian, guardianship or safeguard of justice), or unable of expressing his / her consent.
✕. Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons 4. History of malignant disease in the 5 years prior to inclusion (except basal cell carcinoma of the skin or epithelioma of the cervix in situ, or prostate cancer with a good prognosis (stage T \<3 and Gleason \<7)) accidentally discovered during the histological analysis of the tumor sample.

What they're measuring

Plasma level of the MMP2 and MMP9 markers

Timeframe: at initial sampling

Survival without progression

Timeframe: Up to 18 months

Trial details

NCT IDNCT03185039

SponsorInstitut Paoli-Calmettes

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-19

View on ClinicalTrials.gov More Kidney Cancer trials